Form 4 for LAB STANDARD BIOTOOLS INC.
Accepted 2024-04-05 00:00:00 ET · period of report 2024-01-05 · accession 0000950170-24-042373 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-04-05 | 2024-01-05+ | LAB | Egholm Michael | Pres, CEO, Dir | A - Grant | $0.00 | +221.1K | 634.2K | +54% | $0 |
| D | 2024-04-05 | 2024-04-04 | LAB | Egholm Michael | Pres, CEO, Dir | M - OptEx | $0.00 | +196.5K | 422.0K | +87% | $0 |
| D | 2024-04-05 | 2024-04-04 | LAB | Egholm Michael | Pres, CEO, Dir | M - OptEx | $0.00 | -196.5K | 393.0K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-05 | A | A | 9,006 | $0.00 | 225,518 | D | — | — | (F1) Received in exchange for 8,114 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger, dated October 4, 2023, by and among Standard BioTools Inc. (the "Issuer"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Issuer's common stock at the effective time of the Merger. |
| 2 | Common | Common Stock | 2024-04-05 | A | A | 212,126 | $0.00 | 634,156 | D | — | — | (F2) On April 11, 2023, the Reporting Person was granted a target amount of 231,579 performance-based restricted stock units ("RSUs") under the Issuer's 2011 Equity Incentive Plan, as amended. Each RSU represent the right, upon achievement of certain pre-established performance criteria, to receive one share of the Issuer's common stock, subject to vesting conditions. On April 5, 2024, the Board of Directors of the Issuer determined that certain of the RSU performance-based conditions were met resulting in the vesting of 212,126 RSUs as of March 31, 2024. |
| 3 | Common | Common Stock | 2024-04-04 | M | A | 196,512 | $0.00 | 422,030 | D | — | — | |
| 4 | Derivative | Restricted Stock Units | 2024-04-04 | M | D | 196,512 | $0.00 | 393,025 | D | — · — to — | 196,512 Common Stock | (F3) Each RSU represents the contingent right to receive one share of the Issuer's common stock. (F4) On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023. |